View Item 

Show simple item record

Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper
dc.contributor.authorWorthington, Patricia
dc.contributor.authorGura, Kathleen M.
dc.contributor.authorKraft, Michael D.
dc.contributor.authorNishikawa, Reid
dc.contributor.authorGuenter, Peggi
dc.contributor.authorSacks, Gordon S.
dc.date.accessioned2021-03-02T21:42:59Z
dc.date.available2022-03-02 16:42:58en
dc.date.available2021-03-02T21:42:59Z
dc.date.issued2021-02
dc.identifier.citationWorthington, Patricia; Gura, Kathleen M.; Kraft, Michael D.; Nishikawa, Reid; Guenter, Peggi; Sacks, Gordon S. (2021). "Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper." Nutrition in Clinical Practice 36(1): 29-39.
dc.identifier.issn0884-5336
dc.identifier.issn1941-2452
dc.identifier.urihttps://hdl.handle.net/2027.42/166352
dc.description.abstractIntravenous in‐line filters play a critical role in promoting patient safety during parenteral nutrition (PN) administration. Guidelines for using filters for PN have been issued by a number of professional organizations and manufacturers of PN components. Yet despite this guidance, filter use remains controversial. Recent changes in recommendations for filtering lipid injectable emulsions have added to confusion and created considerable variation in practice. This Position Paper aims to review past guidance regarding the filtration of PN, examine the clinical consequences of infusing particulate matter, discuss the challenges and issues related to filtration, and clarify the American Society for Parenteral and Enteral Nutrition (ASPEN) recommendations for the use of filters for PN administration. This paper was approved by the ASPEN Board of Directors.
dc.publisherWiley Periodicals, Inc.
dc.publisherThe United States Pharmacopeial Convention
dc.subject.otherlipid injectable emulsion
dc.subject.otherparenteral nutrition
dc.subject.otherpatient safety
dc.subject.otherintravenous fat emulsions
dc.subject.otherfilters
dc.titleUpdate on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166352/1/ncp10587_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166352/2/ncp10587.pdf
dc.identifier.doi10.1002/ncp.10587
dc.identifier.sourceNutrition in Clinical Practice
dc.identifier.citedreferenceKrishna A, Rice M, Kester T, Waters M, Wilson T. Particulate study on NeoProfen, a neonatal injectable product. PDA J Pharm Sci Technol. 2016; 70 ( 1 ): 76 ‐ 92.
dc.identifier.citedreferenceTrissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of medications with 3‐in‐1 parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr. 1999; 23 ( 2 ): 67 ‐ 74.
dc.identifier.citedreferenceLehr H‐A, Brunner J, Rangoonwala R, Kirkpatrick CJ. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med. 2002; 165 ( 4 ): 514 ‐ 520.
dc.identifier.citedreferencePerez M, Decaudin B, Maiguy‐Foinard A, et al. Dynamic image analysis to evaluate subvisible particles during continuous drug infusion in a neonatal intensive care unit. Sci Rep. 2017;7(1):9404. https://doi.org/10.1038/s41598-017-10073-y
dc.identifier.citedreferenceTownsley MI. Structure and composition of pulmonary arteries, capillaries and veins. Compr Physiol. 2013; 2 ( 1 ): 675 ‐ 709.
dc.identifier.citedreferenceShay DK, Fann LM, Jarvis WR. Respiratory distress and sudden death associated with receipt of a peripheral parenteral nutrition admixture, Infect Control Hosp Epidemiol. 1997; 18 ( 12 ): 814 ‐ 817.
dc.identifier.citedreferenceMcNearney T, Bajaj C, Boyars M, Cottingham J, Haque A. Total parenteral nutrition associated crystalline precipitates resulting in pulmonary artery occlusions and alveolar granulomas. Dig Dis Sci. 2003; 48 ( 7 ): 1352 ‐ 1354.
dc.identifier.citedreferenceReedy JS, Kuhlman JE, Voytovich M. Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high‐ resolution CT findings. Chest. 1999; 115 ( 3 ): 892 ‐ 895.
dc.identifier.citedreferenceMelchore JA. Sound practices for consistent human visual inspection. AAPS Pharm Sci Tech. 2011; 12 ( 1 ): 215 ‐ 221.
dc.identifier.citedreferenceDas T, Nema S. Protein particulate issues in biologics development. Am Pharm Rev. 2008; 11 ( 3 ): 52 ‐ 57.
dc.identifier.citedreferenceCorvari V, Narhi LO, Spitznagel TM, et al. Subvisible (2‐100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Biologicals. 2015; 43 ( 6 ): 457 ‐ 473.
dc.identifier.citedreferenceJack T, Brent BE, Muller M, et al. Analysis of particulate contamination of infusion solutions in pediatric intensive care unit. Intensive Care Med. 2010; 36 ( 4 ): 707 ‐ 711.
dc.identifier.citedreferenceBall PA, Bethune K, Fox J, et al. Particulate contamination in parenteral nutrition solutions: still a cause for concern. Nutrition. 2001; 17: 926 ‐ 929.
dc.identifier.citedreferenceHardy G, Puzovic M. Formulation, stability, and administration of parenteral nutrition with new lipid emulsions. Nutr Clin Pract. 2009; 24 ( 5 ): 616 ‐ 25.
dc.identifier.citedreferenceUnited States Pharmacopeia. Chapter <729>. Globule Size Distribution in Lipid Emulsions. In: The United States Pharmacopeia, 36th rev, and the National Formulary. Rockville, MD: United States Pharmacopeia; 2019.
dc.identifier.citedreferenceFDA Intralipid Alerts. Drugs.com. Accessed December 16, 2019. https://www.drugs.com/fda-alerts/1067-9297.html
dc.identifier.citedreferenceFood and Drug Administration. Intralipid 20 Percent IV Fat Emulsion by Baxter: Recall ‐ One Shipment of Product Exposed to Subfreezing Temperatures. Published October 5, 2017. Accessed September 2, 2020. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-initiates-voluntary-nationwide-recall-one-shipment-intralipid-20-iv-fat-emulsion-due-product
dc.identifier.citedreferencePerez M, Decaudin B, Abou Chala W, et al. In vitro analysis of overall particulate matter contamination exposure during multidrug IV therapy: Impact of infusion sets. Pediatr Blood Cancer. 2015; 62 ( 6 ): 1042 ‐ 1047.
dc.identifier.citedreferencePerez M, Decaudin B, Chahla WA, et al. Effectiveness of in‐line filters to completely remove particulate contamination during a pediatric multidrug infusion protocol. Sci Rep. 2018; 8 ( 1 ): 1 ‐ 8.
dc.identifier.citedreferenceJack T, Boehne M, Brent BE, et al. In‐line filtration reduces severe complications and length of stay on pediatric intensive care unit: A prospective, randomized, controlled trial. Intensive Care Med. 2012; 38 ( 6 ): 1008 ‐ 1016.
dc.identifier.citedreferenceBenlabed M, Martin Mena A, Gaudy R,et al. Analysis of particulate exposure during continuous drug infusion in critically ill adult patients: a preliminary proof‐of‐concept in vitro study. Intensive Care Med Exp. 2018; 6 ( 1 ): 38.
dc.identifier.citedreferenceFoster JP, Richards R, Showell MG, Jones LJ. Intravenous in‐line filters for preventing morbidity and mortality in neonates. Cochrane Database Syst Rev. 2015;( 8 ): CD005248.
dc.identifier.citedreferenceSchmitt E, Meybohm P, Herrmann E, et al. In‐line filtration of intravenous infusion may reduce organ dysfunction of adult critical patients. Crit Care. 2019; 23: 373.
dc.identifier.citedreferenceGill M. Filtering out the Facts: Recommendations to Optimize Performance of In‐Line Filters for Parenteral Nutrition and Intravenous Fat Emulsion Infusions. BD. Published August 2019. Accessed January 27, 2020. https://www.bd.com/en-us/clinical-excellence/bd-institute-for-medication-management-excellence/blog/key-insights-from-a-recent-white-paper-on-the-performance-of-in-line-filters-for-parenteral-nutrition-and-intravenous-fat-emulsion-infusions
dc.identifier.citedreferenceChau D, Gish B, Tzanetos D, Zhang C. A dangerous side of in‐line filter when used for vasoactive infusions in infants. APSF newsletter. 2013;28( 2 ):43
dc.identifier.citedreferenceIV in‐line Filter FAQs. CareFusion 2010. Published 2010. Accessed October 5, 2020. https://www.bd.com/documents/faq/IF_Alaris-Pump-Module_FQ_EN.pdf
dc.identifier.citedreferenceNewton DW. Y‐site compatibility of intravenous drugs with parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013; 37 ( 3 ): 297 – 299.
dc.identifier.citedreferenceCanadian Vascular Access Association. Occlusion management guideline for central vascular access devices (CVADs). J Can Vascular Access Assoc. 2013; 7 ( Suppl. 1 ): 3 – 31.
dc.identifier.citedreferenceSacks GS, Rough S, Kudsk KA. Frequency and severity of harm of medication errors related to the parenteral nutrition process in a large university teaching hospital. Pharmacotherapy. 2009; 29 ( 8 ): 966 ‐ 974.
dc.identifier.citedreferenceAyers P, Adams S, Boullata J, et al. American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. Parenteral nutrition safety consensus recommendations. JPEN J Parenter Enteral Nutr. 2014; 38: 296 ‐ 333.
dc.identifier.citedreferenceBoullata JI, Gilbert K, Sacks GS, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr. 2014; 38 ( 3 ): 334 ‐ 377.
dc.identifier.citedreferenceFood and Drug Administration safety alert: Hazards of precipitation associated with parenteral nutrition. Am J Hosp Pharm. 1994; 51 ( 11 ): 1427 ‐ 1428.
dc.identifier.citedreferenceAmerican Society for Parenteral and Enteral Nutrition (ASPEN). Parenteral Nutrition—New Recommendations for In‐line Filters. Accessed September 2, 2020. http://www.nutritioncare.org/News/General_News/Parenteral_Nutrition_%E2%80%93_New_Recommendations_for_In-line_Filters/
dc.identifier.citedreferenceInfusion Nurses Society. Infusion therapy standards of practice. J Infus Nurs. 2016; 2016 ( 1S ): S11 ‐ S159.
dc.identifier.citedreferenceCohen MR, Smetzer JL. ISMP medication error report analysis. Selected medication safety risks to manage in 2016–Part I intravenous fat emulsion needs a filter. Hosp Pharm. 2016; 51 ( 5 ): 353 ‐ 357.
dc.identifier.citedreferenceISMP Medication Safety Alert. ISMP Quarterly Action Agenda. Accessed September 2, 2020. https://www.ismp.org/sites/default/files/attachments/2018-02/ActionAgenda1602.pdf
dc.identifier.citedreferenceBethune K, Allwood M, Grainger C, Wormleighton C. Use of filters during the preparation and administration of parenteral nutrition: Position paper and guidelines prepared by a British pharmaceutical nutrition group working party. Nutrition. 2001; 17 ( 5 ): 403 ‐ 408.
dc.identifier.citedreferencePuntis J, Hojsak I, Ksiazyk J; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: organizational aspects. Clin Nutr. 2018; 37 ( 6 Pt B ): 2392 ‐ 2400.
dc.identifier.citedreferenceMartindale RG, Berlana D, Boullata JI, et al. Summary of proceedings and expert consensus statements from the international summit “Lipids in Parenteral Nutrition”. JPEN J Parenter Enteral Nutr. 2020; 44 Suppl 1: S7 ‐ S20.
dc.identifier.citedreferenceChristensen ML, Ayers P, Boullata JI, et al. Lipid injectable emulsion survey with gap analysis. Nutr Clin Pract. 2017; 32 ( 5 ): 694 ‐ 702.
dc.identifier.citedreferenceBall P. Intravenous in‐line filters: filtering the evidence. Currt Opin Clin Nutr. 2003; 6 ( 3 ): 319 ‐ 325.
dc.identifier.citedreferencePuntis JWL, Wilkins KM, Ball PA, Rushton DI, Booth IW. Hazards of parenteral treatment: do particles count? Arch Dis Child. 1992; 67 ( 12 ): 1475 ‐ 147
dc.identifier.citedreferenceBenlabed M, Perez M, Gaudy R, et al. Clinical implications of intravenous drug incompatibilities in critically ill patients. Anesth Crit Care Pain Med. 2019; 38 ( 2 ): 173 ‐ 180.
dc.identifier.citedreferenceFiltration Devices for Infusion Therapy & Drug Delivery. Pall Corporation. Published 2020. Accessed September 2, 2020. https://medical.pall.com/en/oem-manufacturing/filter-devices/liquid-filtration.html
dc.identifier.citedreferenceBoehne M, Jack T, Köditz H, et al. In‐line filtration minimizes organ dysfunction: new aspects from a prospective, randomized, controlled trial. BMC Pediatr. 2013; 13: 21.
dc.identifier.citedreferenceMcKinnon BT. FDA safety alert: hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract. 1996; 11 ( 2 ): 59 ‐ 65.
dc.identifier.citedreferenceDriscoll DF, Bacon MN, Bistrian B. Effects of in‐line filtration on particle size in total nutrient admixtures. JPEN J Parenter Enteral Nutr. 1996; 20 ( 4 ): 296 ‐ 301.
dc.identifier.citedreferenceMatlow AG, Kitai I, Kirpalani H, et al. A randomized trial of 72‐ versus 24‐hour intravenous tubing set changes in newborns receiving lipid therapy. Infect Control Hosp Epidemiol. 1999; 20: 487 ‐ 493.
dc.identifier.citedreferenceDavis NN, Turco S, Sivelly E. Particulate matter in I.V. infusion fluids. Bull Parenter Drug Assoc. 1970; 24(6): 257 ‐ 270.
dc.identifier.citedreferenceDavis NM, Turco S, Sivelly E. A study of particulate matter in I.V. infusion fluids. Am J Hosp Pharm. 1970; 27 ( 10 ): 822 ‐ 826.
dc.identifier.citedreferenceDavis NM, Turco S. A study of particulate matter in I.V. Infusion fluids—Phase 2. Am J Hosp Pharm. 1971; 28 ( 8 ): 620 ‐ 623.
dc.identifier.citedreferenceTurco SJ, Davis NM. Particulate matter in intravenous infusion fluids—Phase 3. Am J Hosp Pharm. 1973; 30 ( 7 ): 611 ‐ 613.
dc.identifier.citedreferenceHill SE, Heldman LS, Goo ED, Whippo PE, Perkinson JC. Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr. 1996; 20 ( 1 ): 81 ‐ 87.
dc.identifier.citedreferenceKnowles, JB, et al, Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989; 13 ( 2 ): 209 – 213.
dc.identifier.citedreferenceRobinson LA, Wright BT. Central venous catheter occlusion caused by body‐heat‐mediated calcium phosphate precipitation. Am J Hosp Pharm. 1982; 39 ( 1 ): 120 ‐ 121.
dc.identifier.citedreferenceBreaux CW Jr, Duke D, Georgeson KE, Mestre JR. Calcium phosphate crystal occlusion of central venous catheters used for total parenteral nutrition in infants and children: prevention and treatment. J Pediatr Surg. 1987; 22 ( 9 ): 829 – 832.
dc.identifier.citedreferenceMaki DG, Goldman Dam Rhame FS. Infection control in intravenous therapy. Ann Intern Med. 1973; 79 ( 6 ): 867 ‐ 887.
dc.identifier.citedreferenceWilmore DW, Dudrick SJ. An in‐line filter for venous solutions. Arch Surg. 1969; 99 ( 4 ): 462 ‐ 463.
dc.identifier.citedreferenceJornitz MW, Akers, JE, Agalloco JP, Madsen RE, Meltzer TH. Considerations in sterile filtration. Part II: the sterilizing filter and its organism challenge: a critique of regulatory standards. PDA J Pharm Sci Technol. 2003; 57 ( 2 ): 88 ‐ 96.
dc.identifier.citedreferenceO’Grady NP, Dellinger EP, Gerberding JL, et al. Guidelines for the prevention of intravascular‐catheter related infections. Morb Mortal Wkly Rep (MMWR). 2002; 51 ( RR‐10 ): 1 ‐ 29.
dc.identifier.citedreferenceOie S, Kamiya A. Particulate and microbial contamination in in‐use admixed parenteral nutrition solutions. Biol Pharm Bull. 2005; 28 ( 12 ): 2268 ‐ 2270.
dc.identifier.citedreferenceO’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter‐related infection. Clin Infect Dis. 2011; 52 ( 9 ): e162 ‐ e193.
dc.identifier.citedreferenceUnited States Pharmacopeia. Pharmaceutical compounding—sterile preparations (Chapter 797). In: The United States Pharmacopeia, 36th rev, and the National Formulary. Rockville, MD: The United States Pharmacopeial Convention; 2008.
dc.identifier.citedreferenceMirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004; 28 ( 6 ): S39 ‐ S69.
dc.identifier.citedreferenceHirsch A. In line filters and injectable lipid emulsions. GASPEN Newsletter. 2019;(5): 6 ‐ 9.
dc.identifier.citedreferenceIntralipid 20%. Package insert. Fresenius Kabi; 2015.
dc.identifier.citedreferenceNutrilipid. Package insert. B. Braun Medical Inc; 2017.
dc.identifier.citedreferenceClinolipid. Package insert. Baxter Healthcare Corporation; 2016.
dc.identifier.citedreferenceSMOFlipid. Package insert. Fresenius Kabi; 2015.
dc.identifier.citedreferenceOmegaven. Package insert. Fresenius Kabi; 2018.
dc.identifier.citedreferenceVA Comprehensive Pharmacovigilance Center. Intralipid IV fat emulsion products in Biofine containers: particulate matter observed. Medication Safety Seconds. 2016; 6 ( 1 ): 3.
dc.identifier.citedreferenceUnited States Pharmacopeia. Chapter <788>Particulate Matter in Injections. USP 35. In: The United States Pharmacopeia, 36th rev, and the National Formulary. Rockville, MD: US Pharmacopeial Convention; 2013.
dc.identifier.citedreferenceTran T, Kupiec TC, Trissel LA. Particulate matter in injections: what is it and what are the concerns. Int J Pharm Compounding. 2006; 10 ( 3 ): 202 ‐ 204
dc.identifier.citedreferenceLangille SE. Particulate matter in injectable drug products. PDA J Pharm Sci Tech. 2013; 67 ( 3 ): 186 ‐ 200.
dc.identifier.citedreferencePerez M, Maiguy‐Foinard A, Barthelemy C, Decaudin B, Odou P. Particulate matter in injectable drugs: evaluation to risks to patients. Pharm Technol Hosp Pharm. 2016; 1 ( 2 ): 91 ‐ 103.
dc.identifier.citedreferenceGordon S. Sacks, filtration of parenteral nutrition admixtures: friend or foe. Nutrition. 1997; 13 ( 10 ): 936 ‐ 937.
dc.identifier.citedreferenceNewton DW, Driscoll DF. Calcium and phosphate compatibility: revisited again. Am J Health Syst Pharm. 2008; 65 ( 1 ): 73 ‐ 80.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ncp10587_am.pdf
Size:
823.3KB
Format:
PDF
View/Open
Name:
ncp10587.pdf
Size:
568.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.